COMPASS BIOTECHNOLOGIES (COBI:OB) ANNOUNCES SUPPLEMENTARY PRESS RELEASE FOR NEW WEBSITE

www.compassbio.net

EDMONTON, April 13 /PRNewswire/ - COMPASS Biotechnologies (OTCBB:COBI) It has come to the Company's attention that in the previous Press Release of today (April 13,2011) that some of the hyperlinks to our website at www.compassbio.net  may not have been properly established directly from the original press release as intended.

This supplementary press release is therefore an update notice that Compass Biotechnologies has launched its new website at www.compassbio.net  and wishes to apologize for any inconvenience the mislinking may have caused.

About Compass Biotechnologies

Compass Biotechnologies (COBI: OB) is an Edmonton based biotechnology product development company focused on generic, biosimiliar and biobetter products. From a development perspective, these types of products have lower development costs and lower development risk due to well established mechanisms of action, a known safety profile, with broad clinical indications for physician use. Comparability testing in preclinical and clinical trials will be needed to show the added benefits of the biosimiliar and bio-better drug product.

Compass Biotechnologies also has an wholly owned subsidiary company called C-Pharma Inc.

About C-Pharma  www.c-pharma.net

Compass has also created a private wholly owned subsidiary company called C- Pharma Inc. This Company through its parent Compass; is charged with the creation of a Hepatitis product development franchise.  C-Pharma has acquired the rights to novel vaccine technology which is currently being developed for Hepatitis C applications. This technology was previously developed at the National Institutes of Health (NIH) and licensed to the Company on a worldwide exclusive basis.  In addition C-Pharma is developing its own generics for two drugs known as Ribavirin and pegylated alpha interferon.  These two drugs are currently the drugs used for patients who are chronically infected with the Hepatitis C virus and in combination are the current standard of care.  These two drugs when used together for Hepatitis C chronic infection create a market of $2 billion a year worldwide.

Forward Looking Statements

This news release contains "forward-looking statements", as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Statements in this current report which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors.  Such factors include, among others, the inherent uncertainty of financial estimates and projections, the competitive and regulatory environments, stock market conditions, unforeseen technical difficulties and our ongoing ability to operate a business and obtain financing.  These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that our beliefs, plans, expectations and intentions contained in this current report are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate.  Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our quarterly reports on Form 10-Q and our other periodic reports filed from time-to-time with the Securities and Exchange Commission pursuant to the Securities Exchange Act.

SOURCE Compass Biotechnologies Inc.